SCHEMBL17280459

SCHEMBL17280459

CC(C)(C)OC(=O)Oc1ccccc1-c1ccccc1Op1oc2ccc3ccccc3c2c2c(ccc3ccccc32)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.37
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 2/20 0.32
CYP3A4 P08684 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
CYP2C9 P11712 2/20 0.32
CYP2C19 P33261 2/20 0.32
MAOB P27338 1/20 0.32
TP53 P04637 1/20 0.32
CYP2D6 P10635 1/20 0.32
GAA P10253 3/20 0.32
PGR P06401 1/20 0.32
PTGS1 P23219 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17277956 0.87 ELANE (0.34) KDM4EALDH1A1HSD17B10MEN1CYP3A4
SCHEMBL17280460 0.79 NPC1 (0.32) AHRKDM4EALDH1A1NPC1RAB9A
SCHEMBL17280433 0.77 NPC1 (0.31) NPC1RAB9AL3MBTL1
SCHEMBL17280443 0.77 NPC1 (0.31) NPC1RAB9AL3MBTL1
SCHEMBL17284010 0.76 ABCG2 (0.34) AHRNPC1RAB9AL3MBTL1MEN1
SCHEMBL13627037 0.76 AHR (0.38) AHRNPC1RAB9AL3MBTL1MEN1
SCHEMBL13839496 0.75 L3MBTL1 (0.40) AHRKDM4EALDH1A1HSD17B10NPC1
SCHEMBL17277939 0.74 KMT2A (0.32) MEN1KMT2AMAOBELANE
SCHEMBL19754861 0.74 AHR (0.36) AHRKDM4EALDH1A1HSD17B10NPC1
SCHEMBL17280462 0.73 NPC1 (0.32) NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221850-B2 Monophosphite ligands having a tert-butyloxycarbonyl group EVONIK INDUSTRIES AG (DE) 2015-12-29 US disclosed
US-9221850-B2 Monophosphite ligands having a tert-butyloxycarbonyl group EVONIK INDUSTRIES AG (DE) 2015-12-29 US disclosed
US-20150336988-A1 NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP EVONIK INDUSTRIES AG (DE) 2015-11-26 US disclosed
US-20150336988-A1 NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP EVONIK INDUSTRIES AG (DE) 2015-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336988-A1 NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP TERF2, NUDT1, TERF2IP AHR 517/4885KDM4E 1765/4885ALDH1A1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.